PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO			re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
				Application Number	10/574,054	
INF	ORMATION	I DIS	CLOSURE	Filing Date	March 29, 2006	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Shue, Youe-Kong	
	(Use as many she	aate ae n	acoscáni)	Art Unit	ТВА	
	(occ as many sin			Examiner Name	ТВА	
Sheet	1	of	3	Attorney Docket Number	8031-013-US	

Examiner	Cit-	NON PATENT LITERATURE DOCUMENTS	
⊨xamıner İnitials* ——	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	:	AYRAL, et. al. Rheumatology, Vol 35, 14-17	
		AYRAL, et. al. Annals of the Rheumatic Diseases 2002 vol. 61 suppl. 1	
		HUGHES, et. al. Rheumatology (Oxford) 2002; 41:279-84	
		HEDBOM, et. al. Cell Mol Life Sci 2002; 59:45-53	
		AMIEL et. al. J Orthop Res 1986; 4:162-172	
		ALTMAN et. al. Am J Med. 1983 Oct 31;75(4B):50-5	
· · · · · ·		ADEBOWALE et. al. Biopharm Drug Dispos 2002; 23:217-25	
		AGHAZADEH-HABASHI et. al. J Pharm Pharm Sci 2002; 5(2):181-4	
		CHANG et. al. Osteoarthritis Cartilage 1997; Sep;5:357-72	
		DE MATTEI et. al. Osteoarthritis Cartilage 2002; 10:816-25	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/574,054	
INFORMATION DISCLOSURE	Filing Date	March 29, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Shue, Youe-Kong	
(Use as many sheets as necessary)	Art Unit	ТВА	
(oss as many should as necessary)	Examiner Name	ТВА	
Sheet 2 of 3	Attorney Docket Number	8031-013-US	

Fuendaci	0:4-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ELSAID et. al. Osteoarthritis Cartilage. 2003;11:673-80	
		FINGL et al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1	
		GELETKA et. al. Best Pract Res Clin Rheumatol. 2003 Oct;17:791-809	
		KERIN et. al. Cell Mol Life Sci 2002;59:27-35	
		REGINSTER et. al. Lancet 2001; 357:251-6	
		REISSIG et. al. J. Biol. Chem. 1955 217: 959-966	
		MCALINDON, Best Pract Res Clin Rheumatol 1999; 13(2):329-44	
		SANDY et. al. Arch Biochem Biophys 1999; 367:258-64	
		SHIKHMAN et. al. J Immunol 2001; 166:5155-60	
	<u> </u>	SETTON et. al. Osteoarthritis Cartilage 1999; 7:2-14	

Examiner	Date	
Signature	Considered	,
4=>/		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PTO			re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
				Application Number	10/574,054	
INF		DIS	CLOSURE	Filing Date	March 29, 2006	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Shue, Youe-Kong	
	(Use as many she	ofe ae n	araccand	Art Unit	ТВА	
(ooo ao many anota ao necessary)			vocasary)	Examiner Name	ТВА	
Sheet	3	of	3	Attorney Docket Number	8031-013-US	

Francis (0.4-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SMITH et. al. J Rheumatol 1997; 24:365-71	
		SETNIKER et. al. Arzneimittelforschung 2001; 51:699-725	
		SILVER et. al. Crit Rev Biomed Eng 2001; 29:373-91	
		SAH et. al. J Orthop Res 1997 Mar;15:197-203	
		YOSHIOKA et. al. Osteoarthritis Cartilage 1996; 4:87-98	

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.